Home / Themes / MedTech '24: Fertility & Reproductive Tech

MedTech '24: Fertility & Reproductive Tech (open on stockthemes)

Last updated

Theme thesis · 2/5 sections · Tickers 0 with notes · 11 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Fertility and assisted reproductive technology companies develop, manufacture or deliver the specialized products and services used to overcome infertility and

Thesis

Fertility and assisted reproductive technology companies develop, manufacture or deliver the specialized products and services used to overcome infertility and enable conception. The theme includes IVF laboratory equipment, embryo culture media, cryopreservation technologies, reproductive genetic testing, ovarian-stimulation medicines, fertility treatment providers and fertility-benefits administration. Its economic drivers include assisted reproduction cycle volumes, treatment affordability, insurance coverage, laboratory technology adoption, embryo-development outcomes and expansion of specialized clinic capacity. The basket excludes contraception, routine prenatal care and general gynecology as primary exposures.

Bull case

  • Expansion of employer fertility benefits, insurance coverage and treatment financing increases patient access to IVF, egg freezing and related fertility procedures, supporting higher clinic utilization and recurring laboratory-consumable purchases.

  • Advances in embryo culture media, time-lapse incubation, genetic testing and cryopreservation improve laboratory workflows and embryo selection, encouraging fertility clinics to adopt specialized equipment and premium consumables.

  • Delayed parenthood, greater recognition of infertility and expansion of fertility clinic networks in underserved markets increase demand for ovarian-stimulation medicines, embryology services and assisted reproduction technologies.

Bear case

  • High out-of-pocket treatment costs, limited insurance coverage and household financial pressure constrain patient conversion and reduce the number of completed IVF cycles, especially in markets dependent on self-funded procedures.

  • Embryo-handling errors, laboratory contamination, treatment complications and adverse regulatory findings can result in litigation, clinic disruption and loss of patient confidence in assisted reproduction providers.

  • Competition among fertility clinics and laboratory suppliers, pricing pressure on stimulation medicines and uncertain improvements in live-birth outcomes reduce provider margins and limit willingness to pay for premium reproductive technologies.

Overview

Hiring Trend Watchpoints

High-performing operators in this theme exhibit targeted hiring across three key functions: specialized embryology and lab operations, clinical regulatory affairs, and B2B corporate sales. In clinic networks and embryology laboratories (Monash IVF, Jinxin, Medicover), look for steady postings for senior embryologists, laboratory quality managers, and reproductive endocrinologists; however, persistent shortages are driving concurrent hiring of lab technicians trained on time-lapse incubation and automated image analysis to increase throughput per embryologist. In consumable and device manufacturing (Vitrolife, CooperSurgical, Femasys), high performance is marked by regulatory affairs and clinical quality engineering roles dedicated to navigating EU MDR and FDA 510(k) clearances, alongside specialized territory account executives selling directly to private clinic networks. For fertility benefit managers (Progyny), watch for sales recruitment targeting regional corporate accounts and mid-market employers following the rollout of supplemental plans like Progyny Select, coupled with dedicated patient care navigators. Execution is confirmed by expanding embryology capacity alongside software-driven workflow integration, whereas red flags include hiring freezes in embryology lab personnel, turnover in clinic-level clinical specialists, or contracting corporate sales headcount reflecting employer benefit carve-backs.

Forum Watchlist

  • community_board — r/IVFhigh

    Patient experiences with clinic quality, out-of-pocket stimulation drug costs, insurance denials, and employer fertility benefit coverage rules

  • community_board — r/infertilitymedium

    Technical discussions on protocol changes, stimulation drug efficacy (Gonal-f vs Follistim), PGT-A genetic screening debate, and clinical outcomes

  • professional_network — ASRM Engage Communityhigh

    Embryologist discussions on laboratory automation, culture media lot consistency, time-lapse incubator validation, and regulatory updates

  • professional_network — ESHRE Members Portalmedium

    European clinical practice guideline changes, cryopreservation protocols, single embryo transfer mandates, and quality assurance benchmarking

  • niche_forum — LabRoots Cell & Molecular Biology / Embryology Forumslow

    Advances in cryogenic temperature monitoring, vitrification media stability, and AI-assisted embryo grading algorithms

Industry Publications

  • Fertility and Sterility (fertstert.org) — Official peer-reviewed scientific journal of the American Society for Reproductive Medicine covering clinical ART efficacy, embryo selection, and reproductive genetics.
  • Human Reproduction (academic.oup.com/humrep) — Primary publication of the European Society of Human Reproduction and Embryology, delivering authoritative research on embryology standards and ovarian stimulation guidelines.
  • FemTech World (femtechworld.co.uk) — Dedicated healthcare industry publication tracking commercial deals, venture capital, and clinical rollouts of fertility medtech and laboratory automation.
  • European Medical Journal - Reproductive Health (emjreviews.com) — Specialist clinical review covering congress takeaways, AI embryology innovations, and real-world reproductive medicine practice patterns.
  • IVF Babble (ivfbabble.com) — Prominent fertility and reproductive healthcare platform providing deep reporting on clinic operations, reproductive legislation, and patient access dynamics.

Second Order Trends

The fertility technology sector is moving into a new phase defined by lab automation, less invasive front-line interventions, and corporate benefit democratisation. First, severe global shortages of licensed clinical embryologists are catalyzing clinic adoption of deep-learning embryo assessment software and automated closed-system incubators, evolving AI from an academic novelty into a laboratory productivity tool. Second, alternative in-office and intravaginal technologies (such as directed intratubal insemination and intravaginal culture systems) are gaining traction as lower-cost, lower-intensity interventions before patients commit to high-cost IVF cycles. Third, employer fertility coverage is broadening beyond blue-chip tech firms into middle-market businesses via fully insured supplemental plans, expanding payer-funded cycle volumes. Fourth, legal scrutiny around embryo storage, chain of custody, and personhood has intensified clinic liability, driving multi-facility operators to upgrade cryogenic transport and sensor-enabled dewars with end-to-end audit trails. Finally, price sensitivity and localized regulatory restrictions on donor gametes are driving sustained medical travel across regional clinic hubs in Europe and Asia-Pacific.

Search Keywords Brand Product

  • Gonal-f
  • Pergoveris
  • Follistim AQ
  • EmbryoScope
  • INVOcell
  • FemaSeed
  • FemVue
  • Cryoport Express
  • Cryoshuttle
  • Wallace Aspiration Pump
  • Wallace catheter
  • ORIGIO
  • LifeGlobal
  • Igenomix
  • Smart Cycle
  • Embryo Predict
  • K-Systems
  • FemSperm
  • assisted reproductive technology
  • in vitro fertilization
  • IVF laboratory
  • embryo culture media
  • oocyte cryopreservation
  • preimplantation genetic testing
  • fertility benefits
  • ovarian stimulation

Search Keywords Policy Regulatory

  • mandated fertility coverage
  • ASRM guidelines
  • ESHRE recommendations
  • embryo personhood legislation
  • IVF Protection Act
  • EU Medical Device Regulation IVF

Search Keywords Event Phrases

  • ASRM Scientific Congress
  • ESHRE Annual Meeting
  • Progyny Select launch
  • Wallace Aspiration Pump FDA clearance
  • SART Annual Clinic Report release

Google Trend Product Category Intent

• Gonal-f • Follistim AQ • Pergoveris • INVOcell • FemaSeed • EmbryoScope • PGT-A testing

Google Trend Consumer Intent

• IVF cost out of pocket • egg freezing clinic cost • embryo transfer success rate • employer fertility benefits • infertility treatment insurance coverage • fertility financing options

Google Trend Macro Policy Terms

• IVF insurance mandate • fertility treatment law • embryo legal status • IVF protection bill

Economic Data Watch

1. FRED — Personal Income and Outlays

Matchedfred · access=api · map_only

Metric/field Disposable Personal Income (DPI)

Cadence monthly

Why it matters Higher disposable income can lead to increased willingness and ability to pay for elective fertility treatments, which often have high out-of-pocket costs, directly impacting patient conversion and treatment cycles.

Signal to watch Increasing DPI suggests a more favorable economic environment for patient conversion and treatment cycle initiation.

Confidence: high

2. CMS — National Health Expenditure Accounts (NHEA)

Not in registry

Metric/field Private Health Insurance Expenditures

Cadence annual

Why it matters Growth in private health insurance spending can indicate a healthier overall healthcare market, potentially leading to more comprehensive benefits, including fertility coverage, which is a key bull point for the theme.

Signal to watch Increasing private health insurance expenditures could signal a supportive environment for expanded fertility benefits and reduced patient out-of-pocket costs.

Confidence: medium

3. BLS — Employment Situation

Matched (medium)lab_headcount · access=api

Metric/field Civilian Labor Force Participation Rate (LNS11300000)

Cadence monthly

Why it matters A higher labor force participation rate suggests more individuals are employed and potentially covered by employer-sponsored health plans, increasing the addressable market for fertility benefits providers like Progyny.

Signal to watch An increasing participation rate indicates a growing pool of potential patients with access to employer-sponsored fertility benefits.

Confidence: high

4. CDC / NCHS — National Vital Statistics System

Not in registry

Metric/field General Fertility Rate (Births per 1,000 women aged 15-44)

Cadence annual

Why it matters While the theme addresses infertility, broader trends in fertility rates and delayed parenthood influence the underlying demand for assisted reproductive technologies.

Signal to watch A declining general fertility rate or increasing age of first birth could indicate a growing need for fertility treatments.

Confidence: high

5. FRED — Consumer Price Index

Matchedfred · access=api · map_only

Metric/field Medical Care Services (CPIMEDSL)

Cadence monthly

Why it matters Inflation in medical care services can impact the overall cost of fertility treatments, potentially exacerbating high out-of-pocket expenses and limiting patient access.

Signal to watch Slowing growth or decline in medical care services inflation could alleviate cost pressures on patients and providers.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field New Study Registrations / Enrollment Status Changes for Fertility-Related Trials

Cadence daily

Why it matters New clinical trials or advancements in existing trials for fertility drugs, devices, or procedures can signal future product launches, market innovation, and potential shifts in treatment protocols.

Signal to watch An increase in new trials or positive enrollment status changes suggests ongoing R&D and potential for future growth in the sector.

Confidence: high

2. FDA — Device 510(k) Clearances / PMA Approvals

Not in registry

Metric/field New Device Clearances/Approvals for Reproductive Technology

Cadence daily

Why it matters FDA clearances and approvals for new reproductive technologies and devices (e.g., CooperSurgical's Wallace Aspiration Pump, Femasys's FemaSeed) indicate innovation, market expansion, and potential revenue drivers for theme constituents.

Signal to watch An increase in clearances/approvals for fertility-related devices or drugs suggests a growing and evolving market.

Confidence: high

3. Google Trends — Search Interest

Not in registry

Metric/field Search Volume for 'IVF treatment' and 'egg freezing'

Cadence daily

Why it matters Public search interest for key fertility treatments can serve as a proxy for patient awareness, intent, and underlying demand for services offered by theme members.

Signal to watch Sustained or increasing search interest indicates growing public awareness and potential demand for fertility services.

Confidence: medium

4. USASpending.gov — Federal Contract and Grant Awards

Not in registryaccess=api

Metric/field Federal Awards for 'Reproductive Health' or 'Infertility Research'

Cadence daily

Why it matters Government funding for reproductive health research or services can indicate policy support, drive innovation, and provide direct revenue streams or research opportunities for some theme-related entities.

Signal to watch An increase in federal awards suggests growing government interest and investment in the fertility and reproductive health sector.

Confidence: high

5. Indeed Hiring Lab / LinkedIn — Job Postings Data

Not in registry

Metric/field Job Postings for 'Embryologist' or 'Reproductive Endocrinologist'

Cadence weekly

Why it matters Hiring trends for specialized roles within fertility clinics and labs can indicate expansion plans, clinic utilization, and overall growth in the capacity to deliver fertility services.

Signal to watch An increase in job postings for these specialized roles suggests expansion of fertility clinic networks and increased service demand.

Confidence: medium

Paid Alt Data Watch

1. Komodo Health — Healthcare Map (Claims Data)

Matched (medium)komodo_health_medical_claims · access=file · map_only

Metric/field IVF Cycle Volume (CPT codes for egg retrieval, embryo transfer) by Geography

Cadence monthly

Why it matters Claims data provides direct insight into the volume of IVF cycles and related procedures, which is a core driver for many theme constituents, including clinics (Monash IVF, Jinxin, INVO, Medicover) and suppliers (Vitrolife, CooperSurgical, Merck, Organon).

Signal to watch Increasing IVF cycle volumes indicate growing patient demand and utilization of fertility services.

Confidence: high

2. Earnest Analytics — Consumer Transaction Data

Matched (medium)earnest_analytics_credit_debit_card_consumer_spend · access=file · map_only

Metric/field Spending at Fertility Clinics / Reproductive Health Providers

Cadence weekly

Why it matters Transaction data offers a real-time view of consumer spending on fertility treatments, reflecting out-of-pocket payments and the effectiveness of benefit programs, directly impacting revenue for clinics and benefit administrators like Progyny.

Signal to watch Growth in consumer spending at fertility clinics suggests increased patient engagement and treatment uptake.

Confidence: high

3. Sensor Tower — Web Insights / App Intelligence

Not in registry

Metric/field Website Traffic to Key Fertility Clinic Chains / Benefit Administrators (e.g., progyny.com, monashivf.com)

Cadence weekly

Why it matters Website traffic to major fertility providers and benefit administrators can serve as a leading indicator of patient interest, research activity, and potential new patient inquiries.

Signal to watch Increasing website traffic and engagement suggest growing interest in fertility services and benefits.

Confidence: high

4. Definitive Healthcare — Atlas All-Payor Claims Data

Not in registry

Metric/field Prescription Volume for Ovarian Stimulation Drugs (e.g., Gonal-f, Follistim AQ)

Cadence monthly

Why it matters Prescription volumes for ovarian stimulation drugs directly reflect the number of IVF cycles and ovulation induction procedures being initiated, impacting pharmaceutical companies like Merck and Organon.

Signal to watch Rising prescription volumes for key fertility drugs indicate an increase in treatment starts and demand.

Confidence: high

5. SmartTRAK — IVF Market Reports

Matched (medium)smarttrak_medical_device_market_share_sales_intelligence · access=file · map_only

Metric/field Market Size and Growth Rates for IVF Consumables and Equipment

Cadence quarterly

Why it matters Specialized market research provides in-depth analysis of the fertility market, including trends in consumables, equipment, and genetic testing, which are crucial for understanding the performance of companies like Vitrolife and CooperSurgical.

Signal to watch Positive growth trends in market segments relevant to theme constituents indicate a healthy and expanding market.

Confidence: high

Prediction Market Watch

1. Will Minnesota medical-device manufacturing jobs rise YoY? (2026)

Kalshi · Confidence: medium

Not in registryaccess=api

Market https://kalshi.com/markets/kxmnmeddevemp

Why it matters A rise in medical-device manufacturing jobs in Minnesota, a significant hub for the medical device industry, could indicate broader positive trends in the MedTech sector. This includes potential growth in demand and production for fertility and reproductive technologies, which would benefit theme constituents involved in manufacturing equipment and consumables like Vitrolife and CooperSurgical.

Series key pm_mn_meddev_jobs_yoy_rise

2. Will New Jersey pharmaceutical manufacturing jobs rise YoY? (2026)

Kalshi · Confidence: medium

Not in registryaccess=api

Market https://kalshi.com/markets/kxnjpharmaemp

Why it matters An increase in pharmaceutical manufacturing jobs in New Jersey, a major pharmaceutical hub, could signal a healthy and growing pharmaceutical sector. This is relevant to theme constituents like Merck and Organon, which manufacture ovarian-stimulation medicines crucial for IVF treatment cycles. Growth in this area could indicate sustained or increased demand for their products.

Series key pm_nj_pharma_jobs_yoy_rise

Theme Plain English
Fertility and reproductive technology companies develop products and services that treat infertility and assist conception. The theme spans specialized in vitro fertilization laboratory equipment, culture media, cryopreservation systems, and genetic testing consumables, alongside ovulation stimulation therapeutics, cold-chain transport, clinic networks, and employer-sponsored fertility benefit managers. Aging maternal demographics, expanding insurance mandates, and laboratory automation drive cycle volume and technology adoption worldwide.

News

1 story tagged to this theme — Narrative Radar and editorial picks.

October 2026

Loading correlation…

Constituents

  • 1951.HKT3
    · no notes yet
  • COOT3
    · no notes yet
  • CYRXT3
    · no notes yet
  • FEMYT3
    · no notes yet
  • IVFT3
    · no notes yet
  • MCOV-B.STT3
    · no notes yet
  • MRK.XETRAT3
    · no notes yet
  • MVF.AUT3
    · no notes yet
  • OGNT3
    · no notes yet
  • PGNYT3
    · no notes yet
  • VITR.STT3
    · no notes yet